Login
Companies $DHR
$232.38 -$0.60 (0.26%) Live
Danaher Corporation logo

Danaher Corporation

danaher.com

What Do They Do?

Sells equipment, consumables and services for biological medicine production, life sciences research and medical diagnostics to drug and biotechnology companies, research organizations, and hospitals and laboratories.

How Do They Make Money?

Danaher sells equipment and consumables in one-time sales; services, extended warranties and operating-type leases generate revenue over their terms, while some long-term contracts generate revenue as work progresses.

revenue
SegmentShareRevenue
Recurring
Mix

82%
FY2022: 78%
Nonrecurring
Mix

18%
FY2022: 22%

Who Are Their Customers?

Pharmaceutical and biotechnology companies, research organizations, hospitals and laboratories buy Danaher's products through its sales teams and independent distributors.

Do Revenues Turn Into Profits?

Yes. It kept 15 cents of every revenue dollar as net income in FY2025 and turned 21 cents into free cash flow.

Operating income, FY2025
19% of revenue
▼ −4% vs FY2024 ($4.9B, 20%)
Net income, FY2025
15% of revenue
▼ −7% vs FY2024 ($3.9B, 16%)
Free cash flow, FY2025
21% of revenue
▼ −1% vs FY2024 ($5.3B, 22%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 25, 2026
Revenue
▲ +8%
vs $6.1B in Q3 FY2025
Net income
▲ +36%
vs $908M in Q3 FY2025
Recurring revenue share of revenue vs 82.9% in Q3 FY2025
  • Oct 21, 2026 Danaher raised full-year adjusted earnings-per-share guidance Full-year 2026 guidance rose to $8.57 to $8.62, from the previous range of $8.45 to $8.60.
  • Aug 3, 2026 Julie Sawyer Montgomery became CEO as Rainer Blair retired Montgomery took the role effective October 1; Blair was to serve as a senior advisor until March 31, 2027.

Flat. Revenue was $24.6B in FY2025, about the same as the $24.8B of FY2021.

Segment portfolio The older report includes Environmental & Applied Solutions as a segment, while the latest describes biotechnology, life sciences and diagnostics segments.

Revenue over time
Recurring Nonrecurring
$50B$25B$0

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support